9:00am - 5:00pm

Office Hours Mon. - Fri.


Call Us For Free Consultation



A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Estimated reading time: < 1 min


Pleural Mesothelioma|Peritoneal Mesothelioma

Estimated Enrollment: 40

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: NIBIT-MESO-1

Study First Received: October 26, 2015

Last Updated: October 26, 2015

Estimated Primary Completion Date: June 2016

Primary Outcome Measures:

immune-related (ir)- objective response rate (ORR)|Immune-related-Disease control rate (ir-DCR)|Disease control rate (DCR)|Immune-related-progression-free-survival (PFS)|progression-free-survival (PFS)|Overall survival (OS)|Safety (adverse events)|Immune-related-ORR based on PD-L1 tumor expression|Immune-related-Disease control rate based on PD-L1 tumor expression|Immune-related-progression- free-survival based on PD-L1 tumor expression|Overall survival based on PD-L1 tumor expression

Sponsors and Collaborators:

Italian Network for Tumor Biotherapy Foundation|AstraZeneca

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT02588131

Was this article helpful?
Views: 49